Plain-English translation of NCT05688696 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new drug called orelabrutinib to see if it can help treat systemic lupus erythematosus (SLE), a condition where the immune system attacks the body's own tissues. You would take this medication along with your current lupus treatments to see if it reduces lupus symptoms and disease activity better than a placebo. This is an important step in figuring out whether this new treatment could become an option for people with lupus.
Lupus can be hard to control with current treatments alone, and many patients continue to have active disease despite taking standard medications. Researchers are testing this new treatment to see if it offers better disease control and could give lupus patients another option to help manage their condition.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to take either the new medication at a lower dose, the medication at a higher dose, or a placebo (inactive pill) while continuing your regular lupus medications. You would visit the study clinic multiple times over several months to have blood tests, complete questionnaires about your symptoms, and be checked by doctors to see how you're responding to treatment. The study team will carefully monitor you for any side effects and track changes in your lupus disease activity throughout your participation.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China